ROVI

Pharma

Granules receives Form 483 over poor document controls and more

From truckloads of torn documents to avian incursions, Granules' new manufacturing reprimand from the FDA is alarming no matter which way you read it.

Fraiser Kansteiner Sep 19, 2024 10:11am

Rovi receives offers for potential sale of €2B-plus CDMO group

Jun 27, 2024 2:21pm

Rovi wins FDA nod to make Moderna's COVID shot at Spanish plant

Feb 28, 2024 11:22am